Abstract
Olon, an Italian pharmaceutical services firm with expertise in high-potency active ingredients, will begin manufacturing antibody drug conjugates (ADCs) with the construction of a new plant in Milan. The $23 million facility will be dedicated to manufacturing ultrapotent compounds, which are linked to antibodies as payloads for the production of ADCs. The company expects the first phase of the project, a payload R&D area, to be completed in the first half of 2024; a production line will be installed in a second phase.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
